Oxaliplatin is a platinum analog that can interfere with DNA replication and transcription.
Continuous exposure to oxaliplatin results in chemoresistance; however, this mechanism is not well
known. In Show more
Oxaliplatin is a platinum analog that can interfere with DNA replication and transcription.
Continuous exposure to oxaliplatin results in chemoresistance; however, this mechanism is not well
known. In this study, oxaliplatin-resistant (OR) colorectal cancer (CRC) cells of HCT116, HT29,
SW480 and SW620 were established by gradually increasing the drug concentration to 2.5 µM. The
inhibitory concentrations of cell growth by 50% (IC50 ) of oxaliplatin were 4.40–12.7-fold significantly
higher in OR CRC cells as compared to their respective parental (PT) CRC cells. Phospho-Akt
and phospho-mammalian target of rapamycin (mTOR) decreased in PT CRC cells but was overexpressed in OR CRC cells in response to oxaliplatin. In addition, an oxaliplatin-mediated decrease in
phospho-AMP-activated protein kinase (AMPK) in PT CRC cells induced autophagy. Contrastingly,
an increased phospho-AMPK in OR CRC cells was accompanied by a decrease in LC3B, further
inducing the activity of glycolytic enzymes, such as glucose transporter 1 (GLUT1), 6-phosphofructo2-kinase/fructose-2,6-bisphosphatase 3 (PFKFB3) and phosphofructokinase 1 (PFK1), to mediate
cell survival. Inhibition of AMPK in OR CRC cells induced autophagy through inactivation of
Akt/mTOR pathway and a decrease in GLUT1, PFKFB3, and PFK1. Collectively, targeting AMPK
may provide solutions to overcome chemoresistance in OR CRC cells and restore chemosensitivity to
anticancer drugs.
Human Colorectal Cancer.
Biomedicines 2022, 10, 2690. Show less
2015 · · American Society for Biochemistry and Molecular Biology · added 2026-04-20
Chemokine receptor CCR7 directs mature dendritic cells (mDCs) to secondary lymph nodes where these cells regulate the activation of T cells. CCR7 also promotes survival in mDCs, which is believed to t Show more
Chemokine receptor CCR7 directs mature dendritic cells (mDCs) to secondary lymph nodes where these cells regulate the activation of T cells. CCR7 also promotes survival in mDCs, which is believed to take place largely through Akt-dependent signaling mechanisms. We have analyzed the involvement of the AMP-dependent kinase (AMPK) in the control of CCR7-dependent survival. A pro-apoptotic role for AMPK is suggested by the finding that pharmacological activators induce apoptosis, whereas knocking down of AMPK with siRNA extends mDC survival. Pharmacological activation of AMPK also induces apoptosis of mDCs in the lymph nodes. Stimulation of CCR7 leads to inhibition of AMPK, through phosphorylation of Ser-485, which was mediated by G(i)/Gβγ, but not by Akt or S6K, two kinases that control the phosphorylation of AMPK on Ser-485 in other settings. Using selective pharmacological inhibitors, we show that CCR7-induced phosphorylation of AMPK on Ser-485 is mediated by MEK and ERK. Coimmunoprecipitation analysis and proximity ligation assays indicate that AMPK associates with ERK, but not with MEK. These results suggest that in addition to Akt-dependent signaling mechanisms, CCR7 can also promote survival of mDCs through a novel MEK1/2-ERK1/2-AMPK signaling axis. The data also suggest that AMPK may be a potential target to modulate mDC lifespan and the immune response. Show less